Stellanova Therapeutics

Recent Finacing

Series A

Recent Raise

$15.5M

Stellanova Therapeutics develops cancer therapies targeting carcinoma-associated fibroblasts (CAFs), advancing an anti-DKK3 monoclonal antibody from preclinical pancreatic cancer studies toward first-in-human trials; based at JLABS TMC.

Founded 2019

Texas, United States

1-10

Private

stellanovatx.com

Highlights

Focus Areas

Biotechnology

Health Care

Recent Investors

Financials

$15.5M

Total Raised

1

Funding round

1

Investor

Team

Upgrade to view the team

See the team members at Stellanova Therapeutics.